Oxonc Development LP, of Cayman Islands, said co-development partner Pfizer Inc., of New York, received regulatory approval in Japan and Taiwan to market crizotinib (Xalkori) 200 mg/250 mg capsules for patients with ROS1-positive advanced non-small-cell lung cancer.